Literature DB >> 26310164

Neuroinflammation in Glaucoma and Optic Nerve Damage.

Caitlin E Mac Nair1, Robert W Nickells2.   

Abstract

Glaucoma is a group of optic neuropathies characterized by the degeneration of retinal ganglion cell axons and somas, ultimately preventing light signals in the retina from reaching the brain. Glaucoma is a leading cause of blindness in the world, and treatment options for patients remain limited and minimally efficacious. A number of mechanisms have been linked to glaucomatous pathophysiology. A leading role is now attributed to neuroinflammatory conditions generated by the resident innate immune cells in the optic nerve and retina. Since the eye is immune privileged, the adaptation of these innate immune cells, termed glia, is crucial following trauma. In this chapter, we discuss the mechanisms associated with normal glial function in a healthy eye, and how changes in glial activation can contribute to the process of glaucomatous neurodegeneration in both the optic nerve and retina.
© 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Astrocytes; Glaucoma; Immune privilege; Microglia; Müller cells; Neuroinflammation; Retinal ganglion cells

Mesh:

Year:  2015        PMID: 26310164     DOI: 10.1016/bs.pmbts.2015.06.010

Source DB:  PubMed          Journal:  Prog Mol Biol Transl Sci        ISSN: 1877-1173            Impact factor:   3.622


  36 in total

Review 1.  Peeking into Sigma-1 Receptor Functions Through the Retina.

Authors:  Timur A Mavlyutov; Lian-Wang Guo
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

Review 2.  BAX to basics: How the BCL2 gene family controls the death of retinal ganglion cells.

Authors:  Margaret E Maes; Cassandra L Schlamp; Robert W Nickells
Journal:  Prog Retin Eye Res       Date:  2017-01-04       Impact factor: 21.198

3.  An intraocular drug delivery system using targeted nanocarriers attenuates retinal ganglion cell degeneration.

Authors:  Lei Zhao; Guojun Chen; Jun Li; Yingmei Fu; Timur A Mavlyutov; Annie Yao; Robert W Nickells; Shaoqin Gong; Lian-Wang Guo
Journal:  J Control Release       Date:  2017-01-04       Impact factor: 9.776

Review 4.  Ocular Purine Receptors as Drug Targets in the Eye.

Authors:  Kenneth A Jacobson; Mortimer M Civan
Journal:  J Ocul Pharmacol Ther       Date:  2016-08-30       Impact factor: 2.671

5.  Interaction of Wip1 and NF-κB regulates neuroinflammatory response in astrocytes.

Authors:  Fan Xu; Lifei Chen; Xin Zhao; Haibin Zhong; Ling Cui; Li Jiang; Hui Huang; Li Li; Siming Zeng; Min Li
Journal:  Inflamm Res       Date:  2017-08-05       Impact factor: 4.575

6.  CD200Fc Attenuates Retinal Glial Responses and RGCs Apoptosis After Optic Nerve Crush by Modulating CD200/CD200R1 Interaction.

Authors:  Rong Huang; Qianqian Lan; Lifei Chen; Haibin Zhong; Ling Cui; Li Jiang; Hui Huang; Li Li; Siming Zeng; Min Li; Xin Zhao; Fan Xu
Journal:  J Mol Neurosci       Date:  2017-12-26       Impact factor: 3.444

7.  Rescue of cell death and inflammation of a mouse model of complex 1-mediated vision loss by repurposed drug molecules.

Authors:  Alfred K Yu; Sandipan Datta; Marissa Z McMackin; Gino A Cortopassi
Journal:  Hum Mol Genet       Date:  2017-12-15       Impact factor: 6.150

8.  GDF15 is elevated in mice following retinal ganglion cell death and in glaucoma patients.

Authors:  Norimitsu Ban; Carla J Siegfried; Jonathan B Lin; Ying-Bo Shui; Julia Sein; Wolfgang Pita-Thomas; Abdoulaye Sene; Andrea Santeford; Mae Gordon; Rachel Lamb; Zhenyu Dong; Shannon C Kelly; Valeria Cavalli; Jun Yoshino; Rajendra S Apte
Journal:  JCI Insight       Date:  2017-05-04

9.  BAX-Depleted Retinal Ganglion Cells Survive and Become Quiescent Following Optic Nerve Damage.

Authors:  Ryan J Donahue; Margaret E Maes; Joshua A Grosser; Robert W Nickells
Journal:  Mol Neurobiol       Date:  2019-10-31       Impact factor: 5.590

10.  Immunomodulation as a Neuroprotective Strategy for Glaucoma Treatment.

Authors:  Mine Bariş; Gülgün Tezel
Journal:  Curr Ophthalmol Rep       Date:  2019-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.